Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.

Recruiting now · Phase 2 · Has a placebo group

Conditions studied: Bipolar I Disorder

In brief

Phase II study for patients with Bipolar 1 Disorder experiencing major depressive episode. Patient eligible for enrollment will be randomized (like flipping a coin) to either active drug (LB-102 or placebo). Treatment is for 6 weeks.

Key facts

Study ID

NCT07494305

Run by

LB Pharmaceuticals Inc.

People needed

320

Starts

2026-01-23

Expected to finish

2028-02-01

Last updated by the study team

2026-07-27

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Sign IRB approved ICF, Stable living environment
• Diagnosis of Bipolar1 disorder defined by criteria in the DSM 5 and currently experiencing a MDE without psychotic or mixed features, and supported by the SCID 5 CT
• Currently experiencing an MDE that began at least 4 weeks but no more than 18 months prior to randomization
• Currently treated in an out-patient environment
• MADRS 10 total score ≥24 at both Screening and Baseline with a difference of <20% in scores between visits.
• Clinical Global Impression Scale, Bipolar Version Severity of Illness scale (CGI BP S) depression score ≥4 at both Screening and Baseline.
• YMRS total score ≤12 at both Screening and Baseline.
• Good physical health
• BMI of ≥18 and ≤40 kg/m2.
• Eligibility confirmed centrally for the severity, diagnosis, and treatment history by the SAFER interview.

You may not qualify if…

• Sexually active woman of childbearing potential and male who are not practicing 2 different methods of birth control or woman who is currently breast feeding
• History of non-response to 2 adequate medication trials for depressive symptoms
• Improvement of ≥20% in MADRS 10 total score between the screening and baseline assessments
• Have bipolar disorder with mixed features or considered as rapid cyclers
• Plan to initiate formal cognitive or behavioral therapy, systematic psychotherapy during the study, or plan to initiate such therapy during the study
• History of disorders other than bipolar disorder, confirmed by previous psychiatric evaluation or the DSM 5 within 12 months prior to Screening
• Experience of hallucinations, delusions, or any other psychotic symptomatology in the current MDE attributable to a primary DSM 5 diagnosis other than bipolar disorder.
• Hospitalized for mania associated with Bipolar I Disorder within 30 days prior to Screening. Any previous manic phase must have completely resolved before enrollment in the study.
• Significant risk for suicidal behavior during the study as determined by the Investigator's clinical assessment
• Hypo or hyperthyroidism
• Insulin dependent diabetes
• Uncontrolled hypertension
• Known significant cardiac disease
• Laboratory results outside the defined protocol ranges
• Clinically significant abnormal ECG findings
• Received electroconvulsive therapy (ECT) within 90 days prior to Screening.
• Received Transcranial Magnetic Stimulation within 90 days prior to Screening
• Currently taking prohibited medications as defined in the protocol
• History of non-response and/or responded only to ketamine, ECT or vagus nerve stimulation
• Received GLP-1 within 30 of screening
• History of organ disease that in the opinion of the PI would not make the patient eligible for participation

Where it is running

• Pillar Clinical Research — Bentonville, Arkansas, United States (enrolling)
• Pillar Clinical Research — Little Rock, Arkansas, United States (enrolling)
• CenExel — Bellflower, California, United States (enrolling)
• ProScience Research Group — Culver City, California, United States (enrolling)
• CenExel — Garden Grove, California, United States (enrolling)
• Synergy San Diego — Lemon Grove, California, United States (enrolling)
• NRC Research Institute — Los Angeles, California, United States (enrolling)
• NRC Research Institute — Orange, California, United States (enrolling)
• CenExel — Riverside, California, United States (enrolling)
• CenExel — Torrance, California, United States (enrolling)
• St. Jude Clinical Research — Doral, Florida, United States (enrolling)
• Cenexel Hollywood Florida — Hollywood, Florida, United States (enrolling)
• Innovative Clinical Research — Miami Lakes, Florida, United States (enrolling)
• Health Synergy Clinical Research — West Palm Beach, Florida, United States (enrolling)
• Trialmed — Atlanta, Georgia, United States (enrolling)
• Cenexel Decatur GA — Decatur, Georgia, United States (enrolling)
• Pillar Clinical Research — Chicago, Illinois, United States (enrolling)
• NSRT — Detroit, Michigan, United States (enrolling)
• Arch Clinical Trials — St Louis, Missouri, United States (enrolling)
• Redbird Research — Las Vegas, Nevada, United States (enrolling)
• Manhattan Behavioral Medicine — New York, New York, United States (enrolling)
• Neuro-Behavioral Clinical Research — Canton, Ohio, United States (enrolling)
• Adams Clinical — Philadelphia, Pennsylvania, United States (enrolling)
• Adams Clinical — DeSoto, Texas, United States (enrolling)
• Pillar Clinical Research — Richardson, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.